Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema

Edoardo Midena1,2, Alessandra Micera5, Luisa Frizziero3, Elisabetta Pilotto1, Graziana Esposito2 & Silvia Bini2

Subthreshold micropulse laser (SMPL) is a tissue-sparing technique whose efficacy is demonstrated for diabetic macular edema (DME) treatment. However, its mechanism of action is poorly known. A prospective observational study was performed on naïve DME patients treated with SMPL, to evaluate the changes of aqueous humor (AH) inflammatory and vaso-active biomarkers after treatments. AH samples of eighteen DME eyes were collected before and after SMPL. Ten non-diabetic AH samples served as controls. Full ophthalmic evaluation, spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography were performed in DME group. Glass chip protein array was used to quantify 58 inflammatory molecules. Central retinal thickness (CRT) and visual acuity were also monitored. Several molecules showed different concentrations in DME eyes versus controls (p \text{value} < 0.05). Fas Ligand (FasL), Macrophage Inflammatory Proteins (MIP)-1α, Regulated on Activation Normal T Cell Expressed and Secreted (RANTES) and Vascular Endothelial Growth Factor (VEGF) were increased in DME at baseline versus controls and decreased after SMPL treatments (p < 0.05). CRT reduction and visual acuity improvement were also found. Inflammatory cytokines, mainly produced by the retinal microglia, were significantly reduced after treatments, suggesting that SMPL may act by deactivating microglial cells, and reducing local inflammatory diabetes-related response.

Pathophysiology of diabetic macular edema. Diabetic macular edema (DME) is a common complication of diabetic retinopathy (DR), representing the main cause of visual impairment in these patients1-3. It can occur at any stage of DR and, although widely investigated, its pathogenesis is still controversial4. Several mechanisms have been hypothesized: mainly the breakdown of the blood-retinal barriers4. However, DR and DME cannot be considered anymore as pure microvascular complications of diabetes mellitus (DM). The role of inflammation has recently received great attention as an upstream factor in the pathophysiology of DR and DME5,6. A “low grade” chronic inflammation inside the retina has been hypothesized, and demonstrated in vivo4-7, as a driving factor for the development of both DME and proliferative DR.

Role of retinal glial cells. Retinal glial cells (GLC) are the main actors of retinal inflammatory processes8,9. They are mainly represented by Müller cells and astrocytes, called macroglia, and by the microglia8,9. The role of GLC has been considered mainly structural in the past, whereas an increasing body of scientific evidence shows that they actively maintain the homeostasis of the retinal environment. The main role of Müller cells, biologically connecting retinal neurons and vessels, is to maintain retinal water control. They also participate in the inflammatory response, especially when activated by diabetes8. Microglial cells (MGC) are considered the local immune cells of the retina8, similarly to the central nervous system (CNS) microglial cells. They are activated by stress conditions, such as DM, and are able to change their morphology and function. In the healthy retina, MGC are predominantly localized in the inner retinal layers, in a ramified resting status9. When activated for example...
by diabetes, MGC turn into an ameboid form and gain motility. MGC then migrate toward, from the inner to outer retina, and release pro-inflammatory and vaso-active substances, such as vascular endothelial growth factor (VEGF), contributing to the local inflammatory response followed by increasing vascular permeability19,20.

**Laser therapy for DME.** Because inflammation is a leading cause of DM, therapeutic strategies are aimed to control the over expression of inflammatory cytokines20. Laser photocoagulation has historically represented the main option for the treatment of DME11,12. Subthreshold Micropulse Laser (SMPL) represents a relatively new retinal laser technique13–17. Unlike conventional laser photocoagulation, SMPL is a tissue-sparing technique: it avoids protein coagulation (therefore it is not a photo-coagulation) and prevents retinal scars, allowing retinal anatomic and functional preservation31. It has been hypothesized that SMPL, by inducing a controlled thermal elevation of the retinal tissue, is able to selectively stimulate the retinal pigment epithelium (RPE)12,18. Nevertheless, the precise metabolic changes induced by SMPL are poorly known. The proteomic approach on samples of vitreous body and aqueous humour (AH) of diabetic eyes has significantly contributed to elucidate the pathophysiologic of DME and the effects induced by some different treatments16,19–22. Our group has already demonstrated that SMPL reduces AH biomarkers of Müller cells in treated DME eyes29. The aim of this study was therefore to evaluate if SMPL is also able to influence the concentration of the inflammatory AH biomarkers, specifically produced by MGC in DME eyes. Visual acuity and retinal thickness changes of DME patients, measured by spectral domain optical coherence tomography (SD-OCT), were also evaluated.

**Materials and Methods**

**Population.** A prospective interventional study was performed on DME eyes. The major inclusion criteria were: women or men with type 2 DM; recent HbA1c ≤10%; presence of previously untreated DME, central retinal thickness (CRT) ≤400 μm at Spectral Domain Optical Coherence Tomography (SD-OCT); best corrected visual acuity (BCVA) ≥35 score on ETDRS chart (logMAR 1.0, Snellen 20/200). The main exclusion criteria were: proliferative or severe non proliferative DR; any previous macular treatment (laser photocoagulation, intravitreal injections, vitreo-retinal surgery), any concomitant local treatment (steroid or non-steroidal drugs), post-surgical macular edema of any other etiology; refractive error ≥6 diopters; previous diagnosis of glaucoma or ocular hypertension; concomitant retinal diseases; major neurodegenerative disorders (multiple sclerosis, Alzheimer’s disease etc.); uncontrolled systemic blood pressure, renal failure or systemic disease potentially influencing the protein expression in body fluids; any intraocular surgery in the last 12 months before the beginning of the study; significant media opacity precluding fundus examination. All diabetic patients underwent a full ophthalmologic evaluation, including slit lamp biomicroscopy, intraocular tension measurement, ophthalmoscopic examination for posterior vitreous detachment, any previous ocular surgical procedure, recent (6 months) local treatment of the eye, or patients affected by any significant systemic disease, were excluded from the study, in order to avoid confounding data. Therefore, also control eyes underwent a full ophthalmologic evaluation, in order to exclude any intraocular disorders other than cataract. The informed consent was obtained for each patient of both groups (DME and non-diabetic control group), a certain degree of lens opacification (cataract), not precluding a correct fundus examination and imaging, was present. In non-diabetic control group, AH was sampled once, before standard cataract surgery. Exclusion criteria for non-diabetic control cases were strict: patients with any previous or present ocular disorder, any previous ocular surgical procedure, recent (6 months) local treatment of the eye, or patients affected by any significant systemic disease, were excluded from the study, in order to avoid confounding data. Therefore, also control eyes underwent a full ophthalmologic evaluation, in order to exclude any intraocular disorders other than cataract. The informed consent was obtained for each patient of both groups (DME and non-diabetic subjects), and the research was carried out in accordance with the Declaration of Helsinki regarding experimentation involving human tissue. The approval from the Ethics Committee for Clinical Practice (CESC) of the AOP (Azienda Ospedaliera di Padova) for the study was obtained, with protocol number 3194/AO/14.

**Spectral domain optical coherence tomography.** SD-OCT was performed using Spectralis (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany). Central retinal thickness (CRT) was measured on an En-Face macular map 20° × 20° (5.90 × 5.90 mm). Ninety-seven horizontal scans 60 μm apart were obtained. Automatic real time tracking was on for each acquisition at 50 frames. A linear scan at 180°, length 6 mm was also obtained. Mean retinal thickness was calculated for each of the 9 ETDRS areas (central circle 1 mm diameter, and two external rings 3 and 6 mm diameter). Mean retinal thickness of the entire macular map was measured at each visit. Follow-up modality was set in order to obtain a perfect comparison among the OCT maps and linear scans acquired during one-year follow-up.

**Treatment protocol.** Pupillary dilation and topical anesthesia were performed before SMPL and a Mainster Focal/Grid (Ocular Instrument, Bellevue, WA) lens was used. SMPL treatment was performed with a 577-nm yellow light (Iridex IQ 577; Laser System Iridex Corp, CA), 5% duty cycle of 0.2 seconds, power 250 mW, as already published by our group16,18. No titration was performed, and the same parameters were applied to all patients by a single operator, in order to guarantee comparable results. SMPL was performed in high-density fashion, with multiple and fully confluent spots over the entire area of retinal thickening31. All DME-eyes underwent treatment just after baseline visit. Retreatment was applied 3 months apart, if central subfield OCT macular thickness was ≥300 μm and/or thickness reduction < 50% from baseline in a subfield measured at OCT and/or reduction ≥ 5 letters on the ETDRS chart. A maximum of 4 treatments for each DME patient was applied during the study duration.

**Sample collection, storage and total protein analysis.** The AH samples of DME eyes were collected at baseline, and at 1, 3 and 12 months post first SMPL application, while the sampling of the non-diabetic control group was performed only once, as no changes of proteins’ concentration were expected through the time. All patients underwent the standard preoperative procedure: peri-ocular skin disinfection with povidone-iodine.
10% (ESO-JOD, ECOLAB, Agrate Brianza, Italy), instillation of sterile lidocaine 4% (Alpha Intes, Napoli, Italy), irrigation of conjunctival sac with povidone-iodine 5% (Oftasteril, Alpha Intes) for two minutes and washing of the eye with Balanced Salt Solution (BSS; Alcon, Fort Worth, TX, USA). From the anterior chamber, AH (150–200 μL) was aspirated with an insulin syringe (31-gauge–200ul). AH samples were then collected in a single vial containing 10 μL of a cocktail of protease inhibitors (Pierce Biotechnology, Rock-ford, IL, USA) and quickly stored at −70 °C until analysis. The total protein content was quantified with a digital spectrophotometer (NanoDrop; Thermo Fisher Scientific Inc., Waltham, MA, USA) and protein concentrations were calculated by means of the linearized standard curve (BSA) and the A280 software. Thereafter, AH samples underwent sonication (VibraCell; Sonics, Newton, CT, USA) and centrifugation to collect clear supernatant (13000 rpm/7 min).

Inflammatory profile of protein array. Considering the still unknown mechanism of action of SMPL, the aim of this study was to analyze a wide range of molecules that would hypothetically be influenced in their concentration by this type of laser treatment. Therefore, a customized protein array on glass-chips, from RayBiotech™ technology, established by the manufacturer (Norcross, GA, USA), was used. For the purpose of this study, ELISA was not used immediately, but planned for the further evaluation of the single proteins showing significant changes in this first step analysis with glass-chip array. The array-map included 58 markers. Normalized and pre-diluted AH samples were loaded on chip arrays, according to the manufacturer's instruction, including target, positive, negative and internal control spots. Both diabetic and control groups were processed in parallel. After an overnight incubation at 4 °C, the array slides were washed and exposed to a biotinylated antibody mixture followed by a Cy3-streptavidin labeling solution. All steps were performed under orbital shaking (Certomat II, Sarstorius AG, Göttingen, Germany), with hybridization/washing solutions provided by the kit. Finally, glass-slides were air-dried once with MilliQ water, spin-dried and acquired with GenePix 4400 Microarray scanner (Molecular Devices LLC, Sunnyvale, Silicon Valley, CA, USA). To obtain appropriate Cy3/Cy5 (specific/background signals) images, the slides were scanned over previously validated acquisition parameters and procedures. The fluorescence signals were acquired with the GenePix 4100 microarray scanner (Molecular Devices LLC, Sunnyvale, CA, USA) equipped with the GENEPIX pro 3.0 software (Axon Instruments, Foster City, CA, USA). All comet tails were ignored and only median signal values obtained using the same setting were used for the identification of any biomarker variation. An inter- and intra-assay coefficient of variability limit of ≤10% was set for the study, and a 1.5-fold increase or ≤0.65-fold decrease in signal intensity was considered to guarantee specific signals above background. Fluorescent signals were analyzed and fold changes were generated (pathological/control ratio). The plot of proteins included several interleukins (IL-1β, 4, 6, 8, 10, 11, 12p40, 12p70, 13, 17, 21), Tumor Necrosis Factor (TNF)α, TNFβ, Interferon (INF)γ, Eotaxin, Eotaxin-2, Tissue Inhibitor of Metalloproteinase (TIMP) 1, TIMP-2, TIMP-3, TIMP-4, TNFα converting enzyme (TACE), Intracellular Adhesion Molecule (ICAM)-1, ICAM-2, ICAM-3, Vascular Cell Adhesion Molecule (VCAM)-1, Neural-Cell Adhesion Molecule (NCAM)-1, Osteopontin, Insulin, regulated and normal T cell expressed and secreted (RANTES), Macrophage Inflammatory Protein (MIP)-1α, MIP-1β, MIP-18, MIP-3α, MIP-3β, Toll Like Receptor (TLR)-2, Monocyte Chemo-attractant Protein (MCP)-1, IP-10, Glial cell Derived Neurotrophic Factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF), NeuroTrophin (NT)-3, NT-4, Granulocyte-Colony Stimulating Factor (G-CSF), M-CSF, Placental Growth Factor (PIGF), Nerve Growth factor (NGF), VEGF, TGF β1, Platelet Derived Growth Factor (PDGF)-BB, basic Fibroblast Growth Factor (bFGF), Epidermal Growth Factor (EGF), soluble Tumor Necrosis Factor Receptor (sTNF R)-I, sTNF R-II, VEGF Receptor (VEGF-R)1, VEGF-R2, Insulin-like Growth Factor (IGF)-1, Fas Ligand (FAS L), IL-32, microglobulin (β2M), Albumin. In order to minimize intra- and inter-assay variability, a single tester handled all the material and followed all the phases of the experiment.

Statistical analysis. Results were reported as mean value ± standard deviation. Statistically significant variations of CRT between baseline and follow-up visits, in DME group, were tested using Wilcoxon Signed Rank test. The comparison of AH proteins’ concentration in DME eyes at 1, 3 and 12 months and in non-diabetic control group was made, for each protein, by means of Wilcoxon-Mann-Whitney test. Changes in protein expression in diabetic samples with DME at 1, 3 and 12 months were separately compared to baseline samples and to non-diabetic control cases, and were tested by Wilcoxon signed rank sum test. For these two last analyses Benjamini-Hochberg procedure for multiple-testing correction has been applied choosing a False-Discovery-Rate (FDR). FDR inferior to 20% was set to accept results as statistically significant. All the analyses have been made using SAS® 9.3 statistical software (SAS-Institute, Cary NC, USA) on personal computer. P-value has been interpreted as statistically significant when <0.05 where not otherwise specified.

Results

Demographic characteristics. Eighteen diabetic patients (DM type 2), with non-proliferative DR and DME with CRT below 400 microns were enrolled in this study. Ten non-diabetic patients, planned to undergo cataract surgery, were also enrolled and served as non-diabetic controls. For each patient one eye was considered in the study analyses. All enrolled patients were selected as having the least number of concomitant systemic disorders, such as hypertension, renal impairment or failure, and dyslipidemia. The general characteristics of both study groups are listed in Table 1. No statistically significant differences were found between the two groups (Table 1).

Functional and morphological outcomes. Mean BCV A of DME group at baseline was 77.4 ± 10.1 letters on ETDRS score (0.152 ± 0.021 logMar). All DME eyes were treated at baseline (after sampling AH) and re-treated at each time point (3, 6 and 9 months) of the study, as they satisfied the re-treatment criteria (see materials and methods). A variable number of laser spots depending on the extension of macular edema. BCVA
showed a progressive improvement in number of letters at ETDRS charts compared to baseline, for all the study period: +2.9 ± 4 at 3 months, (+4.6 ± 8.3 at 6 months, (+5.3 ± 8.5 at 9 months and (+6.2 ± 9 at the end of study (12 months). At 3 and 9 months after treatments a statistically significant increase was found (p = 0.047 for both). CRT showed a progressive reduction at each time point during study period. At baseline CRT was 370 ± 37.4 μm, the mean change at 3 months was −14.9 ± 48.9 μm, −12 ± 44.21 at 6 months, −23 ± 36.9 μm at 9 months and −25 ± 40.2 μm at 12 months. Despite the reduction of mean CRT value, the statistically significance was borderline in each time point compared to baseline (p = 0.062 at 9 months and p = 0.078 at 12 months). Comparing the results of fluorescein angiography at 12 months to baseline, no progression of DR or presence of new ischemic areas were found.

Array analysis. Total protein content in the AH samples remained stable during follow up. At baseline, seven proteins showed a significant change of concentration in AH samples of DME group compared to non-diabetic controls (see Tables 2 and 3). Among those, Osteopontin, TIMP 1 and TIMP2 were significantly reduced in DME eyes at baseline versus controls, a further reduction of TIMP2 at 12 months versus baseline was also found (see Table 2). Four proteins, RANTES, FasL, MIP1α and VEGF, showed an increased concentration in DME group at baseline versus non-diabetic controls (Table 3 and Fig. 1) and a significant reduction after treatments at 1 and/or 3 and/or 12 months (Table 4 and Fig. 1). Noteworthy, in DME group, most of the protein concentrations significantly reduced after SMPL treatments during the follow up visits versus baseline values (see Table 4). Even if mean concentration of these proteins at baseline in DME group was increased versus control group, a statistically significant difference was not fully detected. Correlations among each dosed molecule and its changes during the study were correlated with retinal thickness measured on OCT, not only CRT but also single retinal layers changes. However, despite some statistically significant data, these were inconsistent trough time points and were therefore considered unreliable for further considerations.

Discussion
Proteomic studies on biological ocular samples, such as AH or vitreous body, have become more common, in recent years, to investigate retinal diseases. The biodynamic of ocular fluids has demonstrated motion of molecules between the two compartments of the eye (vitreous cavity and anterior chamber)\(^2,3\). Moreover, some Authors have previously demonstrated, in branch retinal vein occlusion and DR, that the aqueous level of VEGF may reflect its vitreous level\(^3,4\). The feasibility of AH sampling is therefore considered appropriate to study the pathophysiology of many retinal disorders, such as DR and DME, and also to evaluate any changes induced by treatments\(^5,6\). Considering AH sampling from the anterior chamber safer than vitreous sampling, in this study, we used a proteomic approach on AH to evaluate the effects of SMPL treatment on protein expression. The therapeutic effects of SMPL are completely different from those of continuous wavelength laser photocoagulation (CWl), the latter causing thermal destruction of the retina. While it is the surviving tissue around the retinal scars that probably mediates the efficacy of CWl, SMPL is a tissue-sparing technique. In fact, the thermal elevation does not induce protein coagulation of the retinal tissue\(^2,3\). It has been hypothesized that SMPL might be able to induce changes of the metabolic activity of the retinal cells, with consequent changes of gene expression and protein secretion\(^1,2,8\). Midena et al. have already demonstrated that AH biomarkers of Müller cells are influenced by SMPL, suggesting that the metabolic activity of these retinal macroglial cells is improved by this laser treatment\(^9,10\). In this study we analyzed 58 proteins, belonging to the inflammatory cascade and produced by several retinal cells, mainly by the MGC. Consistent with a previous paper from our group, comparing patients with and without DR to non-diabetic subjects, we found an increased concentration of some specific inflammatory

### Table 1. General characteristics of the study population and comparison between diabetic group and healthy controls. Abbreviations: DME: diabetic macular edema; M: males; F: females; BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; NA: non applicable; *Chi-square test p-value for sex and presence of hypertension; Wilcoxon-Mann-Whitney otherwise.

|                                | DME baseline (tot. 18) | Controls (tot. 10) | P-value* |
|--------------------------------|------------------------|--------------------|----------|
| Mean Age, mean ± SD            | 63 ± 8.7               | 69 ± 9.8           | 0.515    |
| Sex, M/F                       | 10/8                   | 6/4                | 0.819    |
| Presence of Hypertension, %    | 60%                    | 50%                | 0.569    |
| BP Max, mean ± SD              | 133.4 ± 10.33          | 128 ± 5.7          | 0.559    |
| BP Min, mean ± SD              | 76.67 ± 7.52           | 82.6 ± 4.88        | 0.386    |
| BMI, Kg/m² mean ± SD           | 24.13 ± 1.89           | 26.56 ± 3.47       | 0.350    |
| Cholesterolemia, mg/dl         | 188.2 ± 88.79          | 174.8 ± 38.66      | 0.860    |
| Triglycerides, mg/dl           | 133 ± 36.77            | 140.75 ± 34.33     | 0.831    |
| DM duration, yrs, mean ± SD    | 15.2 ± 10.0            | NA                 | NA       |
| HbA1c, %, mean ± SD            | 7.4 ± 2.6%             | NA                 | NA       |
| Diabetes Treatment             |                        |                    |          |
| Insulin, n (%)                 | 8 (44.45%)             | NA                 | NA       |
| Oral tablets, n (%)            | 9 (50%)                | NA                 | NA       |
| Diet, n (%)                    | 1 (5.56%)              | NA                 | NA       |
**Figure 1.** Representation of proteins’ concentration in non-diabetic subjects (control group) and in DME eyes at baseline and after treatments with SMPL. (A) Representation of RANTES expression; (B) representation of FasL expression; (C) representation of MIP1α expression; (D) representation of VEGF expression. * Indicates statistically significant difference compared to control group, † indicates statistically significant difference compared to baseline. **Abbreviations:** DME: diabetic macular edema; SMPL: subthreshold micropulse laser; TIMP: Tissue Inhibitor of Metalloproteinase.

**Table 2.** Aqueous humour concentration of three proteins in healthy subjects (controls) and in eyes with DME at baseline versus healthy subjects (controls). The results are reported as mean values and standard deviation in brackets of fluorescence intensities signals, measured on glass chip array. P-value = Wilcoxon-Mann-Whitney raw p-value; statistically significant results have been reported in bold characters. The concentration of each protein was significantly reduced in diabetic eyes at baseline versus controls. *p values versus controls; †p values versus baseline **Abbreviations:** DME: diabetic macular edema; SMPL: subthreshold micropulse laser; TIMP: Tissue Inhibitor of Metalloproteinase.

| Protein      | Controls    | DME Group          | P-value* | 1 month | P-value† | 3 months | P-value† | 12 months | P-value† |
|--------------|-------------|--------------------|----------|---------|----------|----------|----------|-----------|----------|
| Osteopontin  | 8907.2 (13143.2) | 548.8 (588.5)     | 0.0007   | —       | 0.0007   | —        | 0.0007   | —         | 0.0007   |
| TIMP         | 473.9 (457.8)    | 141.5 (102.3)     | 0.027    | —       | 0.027    | —        | 0.027    | —         | 0.027    |
| TIMP2        | 28319.0 (28054.8) | 474.1 (782.3)     | 0.006    | —       | 0.006    | —        | 0.006    | —         | 0.006    |

**Table 3.** Aqueous humor concentration of proteins significantly increased in patients with diabetic macular edema at baseline versus healthy subjects (controls). The results are reported as mean values and standard deviation in brackets of fluorescence intensities signals, measured on glass chip array. P-value = Wilcoxon-Mann-Whitney raw p-value; statistically significant results have been reported in bold characters. **Abbreviations:** DME: diabetic macular edema; SMPL: subthreshold micropulse laser; TIMP: Tissue Inhibitor of Metalloproteinase.

| Protein      | Controls    | DME Baseline       | P-value |
|--------------|-------------|--------------------|---------|
| RANTES       | 97.8 (62.7) | 170.3 (85.0)       | 0.048   |
| MIP1α        | 155.1 (102.7) | 285.3 (102.4)  | 0.021   |
| FasL         | 71.6 (116.2) | 124.8 (76.0)      | 0.041   |
| VEGF         | 112.8 (121.2) | 164.2 (129.8) | 0.048   |
### Table 4. Changes of proteins’ expression in the aqueous humor of patients with diabetic macular edema at 1, 3, and 12 months after treatment with Sub-threshold Micropulse Laser, compared to baseline. The results are reported as mean values and standard deviation in brackets of fluorescence intensities signals, measured on glass chip array. P-values: Wilcoxon-Mann-Whitney test. Significant results have been reported in bold characters. *Proteins with significantly increased concentration versus healthy subjects. Abbreviations: β2M = β2-microglobulin; bNGF = basic Nerve Growth Factor; bFGF = basic Fibroblast Growth Factor; FAS L = Fas Ligand; ICAM; Intracellular Adhesion Molecule; MCP: Monocyte Chemo-attractant Protein; MIP: Macrophage Inflammatory Protein; RANTES: regulated and normal T cell expressed and secreted; NT = NeuroTrofin; sTNFR = soluble Tumor Necrosis Factor Receptor; TIMP: Tissue Inhibitor of Metalloproteinase converting enzyme; VCAM: Vascular Cell Adhesion Molecule; VEGF: Vascular endothelial growth factor; VEGFR: VEGF Receptor.

| Protein     | Baseline Mean | After 1 month Mean | Change       | P-value* | Baseline Mean | After 3 months Mean | Change       | P-value* | Baseline Mean | After 12 months Mean | Change       | P-value* |
|-------------|---------------|---------------------|--------------|----------|---------------|---------------------|--------------|----------|---------------|------------------------|--------------|----------|
| β2M         | 4067.5 (3073.7) | 3426.0 (2819.3)    | −641.5 (746.0) | 0.0195   | 4951.5 (4198.8) | 884.1 (1523.3)    | 4260.7 (3734.8) | 193.2 (1113.8) |
| bNGF        | 347.8 (177.6)  | 252.8 (157.1)      | −95.1 (111.7) | 0.0059   | 283.4 (173.2)  | −64.4 (149.4)      | 339.3 (221.8)  | −8.5 (138.5)  |
| bFGF        | 86.9 (46.8)    | 44.8 (30.6)        | −42.1 (48.2)  | 0.0059   | 80.4 (47.2)    | −6.6 (73.3)        | 39.1 (26.2)    | −56.3 (58.7)  | 0.0156 |
| Eotaxin2    | 950.7 (891.8)  | 1039.1 (1298.3)    | 88.4 (476.2)  | 165.6 (137.5) | 0.0019 | 757.3 (624.9)    | −193.4 (336.2) | |
| FAS*        | 124.9 (76.0)   | 57.8 (42.4)        | −66.2 (75.0)  | 0.0098   | 85.5 (40.5)    | −39.4 (79.0)       | 76.6 (39.2)    | −48.3 (85.6)  |
| ICAM1       | 110.4 (58.1)   | 46.2 (60.4)        | −64.2 (24.0)  | 0.0039   | 96.0 (46.9)    | −14.4 (74.5)       | 65.9 (28.5)    | −54.9 (76.6)  |
| ICAM2       | 311.7 (363.6)  | 397.2 (569.6)      | 85.5 (280.4)  | 274.7 (400.4) | −37.0 (115.1) | 1513.1 (1826.2)   | −160.4 (199.9) | 0.0195 |
| MCP1        | 35594.7 (27556.6) | 37340.9 (24670.9) | 1736.2 (5649.2) | 33679.5 (25882.6) | −1915.2 (4243.5) | 29158.6 (23858.7) | −6436.1 (7009.9) | 0.0195 |
| MIP1α*      | 285.4 (102.4)  | 171.4 (57.3)       | −114.0 (72.2) | 0.0019   | 222.5 (107.1) | −62.9 (79.6)       | 247.3 (74.3)   | −38.1 (105.1) |
| MIP3β       | 622.9 (261.7)  | 505.9 (321.4)      | −117.0 (107.6) | 0.0098   | 628.0 (339.2) | 5.1 (154.2)        | 496.7 (303.1)   | −126.2 (143.8) |
| RANTES*     | 170.3 (85.0)   | 102.9 (25.0)       | −68.6 (87.0)  | 0.0156   | 140.6 (125.7) | −24.3 (145.5)      | 93.4 (40.7)    | −76.9 (95.9)  | 0.0273 |
| NT4         | 356.1 (223.0)  | 250.1 (138.7)      | −106.0 (115.0) | 0.0098   | 339.4 (259.1) | −16.8 (139.9)      | 337.7 (181.0) | −18.5 (156.1) |
| sTNFRII     | 952.6 (1149.8) | 1276.6 (1774.5)    | 324.1 (705.8) | 868.6 (1032.4) | −65.8 (236.6) | 622.9 (584.7)    | −329.7 (578.1) | 0.0195 |
| TIMP2       | 474.2 (782.3)  | 592.2 (1391.3)     | 124.0 (649.1) | 392.7 (750.1) | −81.5 (182.9) | 173.8 (286.7)    | −300.4 (510.4) | 0.0137 |
| TIMP3       | 137.1 (69.7)   | 82.7 (24.0)        | −54.4 (57.7)  | 0.0234   | 113.4 (37.0)  | −20.5 (73.7)       | 80.1 (45.2)    | −50.5 (55.6)  | 0.0391 |
| TIMP4       | 125.5 (43.6)   | 87.3 (52.0)        | −36.7 (70.5)  | 0.0122   | 112.2 (66.5)  | −22.0 (83.4)       | 88.2 (41.0)    | −37.3 (42.3)  | 0.0019 |
| VCAM1       | 202.6 (154.9)  | 245.2 (622.0)      | 124.9 (509.2) | 126.1 (186.4) | −35.5 (120.8) | 110.3 (109.1)    | −92.3 (105.7) | 0.0195 |
| VEGFR2      | 390.9 (192.6)  | 353.3 (364.0)      | 44.4 (205.3)  | 0.0156   | 292.3 (265.5) | −16.7 (131.1)      | 235.1 (149.6) | −73.9 (87.2)  | 0.0371 |
| VEGF*       | 164.3 (129.8)  | 190.9 (230.1)      | +26.6 (107.3) | 0.127    | 127.4 (110.3) | −36.9 (39.6)       | 134.7 (140.1) | −29.6 (36.6)  | 0.0456 |

**Proteins with significantly increased concentration versus healthy subjects.**
already mentioned, inflammation has been recently recognized as an important driver of the pathogenesis of DME. Our results suggest that SMPL acts by de-activating MGC and by reducing the production of cytokines and chemokines, including VEGF.

We have also found the reduction of Osteopontin, TIMP1 and TIMP2 concentrations in DME eyes (Table 2). Abu-El-Asrar and co-workers showed an increased concentration of Osteopontin in proliferative diabetic retinopathy, a clinical situation dominated by retinal ischemia. The role of this protein has been more largely investigated in the CNS, specifically in some neurodegenerative disorders, such as Alzheimer’s disease. Osteopontin has both pro-inflammatory and neuro-protective effects, and it is supposed that it modulates the activation and migration of CNS microglia. Sivaprasad et al. confirmed previous results. Metalloproteinases are a group of proteins mainly produced by activated microglia in diabetic retinopathy, which contribute to remodeling the extracellular matrix (ECM); on the contrary, TIMPs (MMPs’ inhibitors) are reduced in DR, leading to imbalanced ECM remodeling. Many other pro-inflammatory cytokines, produced by MGC under stress conditions such as DR and DME (listed in Table 4), showed a significant reduction after the SMPL treatment. Unfortunately, despite their increased mean value in DME eyes at baseline, a statistically significant difference was not fully demonstrated. Moreover, no reliable correlations among retinal thickness changes and proteins’ concentrations were found at each time point, probably because of the low thickness (<400 μm) of the selected DME eyes, and the small sample size. The main limitations of this study, in fact, is the reduced number of eyes. Other limitations of our study, even though minimized by a strict selection of patients, may be represented by possible confounding systemic or local factors that can influence retinal glial activity, or the degree of lens opacification (cataract) in the non-diabetic control group, compared to DME group, which may theoretically influence AH proteins concentration. Larger studies are needed to confirm our first data.

In conclusion, this study shows, for the first time, the effects of SMPL treatment on protein expression in AH samples of patients affected by DME. The significant decrease of RANTES, MIP1α, Fasl and VEGF (pro-inflammatory molecules typically produced by the microglia), suggests that this treatment modality acts by reducing MGC activation. This study contributes to identify possible AH biomarkers of MGC activation and their changes after treatment.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. Lancet 376, 124–136, https://doi.org/10.1016/S0140-6736(09)62124-3 (2010).
2. Bourne, R. R. et al. Vision Loss Expert Group. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health 1, e339–49, https://doi.org/10.1016/S2214-109X(13)70113-X (2013).
3. Yau, J. W. et al. Meta-Analysis for Eye Disease (META- EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35, 556–564, https://doi.org/10.2337/dc11-1909 (2012).
4. Midena, E. & Pilotto, E. Emerging Insights into Pathogenesis. Dev Ophthalmol 60, 16–27, https://doi.org/10.1159/000459687 (2017).
5. El-Asrar, A. M. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol 19, 70–74, https://doi.org/10.4103/0974-9233.92118 (2012).
6. Lee, H. et al. Association between soluble cd14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 59, 715–721, https://doi.org/10.1167/iovs.17-23042 (2018).
7. Bringmann, A. & Wiedemann, P. Müller glial cells in retinal disease. Ophthalmologica 227, 1–19, https://doi.org/10.1159/000328979 (2012).
8. Li, L., Eier, N. & Heiduschka, P. The microglia in healthy and diseased retina. Exp Eye Res 136, 116–130, https://doi.org/10.1016/j.exer.2015.04.020 (2015).
9. Grigsby, J. G. et al. Cardona, P. The microglia in healthy and diseased retina. Exp Eye Res 136, 116–130, https://doi.org/10.1016/j.exer.2015.04.020 (2015).
10. Chhablani, J. et al. Restorative retinal laser therapy: Present state and future directions. Survey Ophthalmol 63, 307–328, https://doi.org/10.1016/j.suronophthal.2017.09.008 (2018).
11. Lu, L., Jiang, Y., Jaganathan, R. & Hao, Y. Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. J Ophthalmal 2018, 1094187, https://doi.org/10.1155/2018/1094187 (2018).
12. Chhablani, J. et al. Subthreshold laser micropulse photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 8, 274–284 (2012).
13. Vujosevic, S. et al. Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues. Curr Med Chem 20, 3267–3271 (2013).
14. Figueria, J. et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmal 93, 1341–1344, https://doi.org/10.1136/bjo.2008.146712 (2009).
15. Vujosevic, S. et al. Microprometry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 30, 908–916, https://doi.org/10.1097/ IAE.0b013e3181c96f86 (2010).
16. Sivaprasad, S., Sandhu, R., Tandon, A., Sayed-Ahmed, K. & McGugh, D. A. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Experiment Ophthalmal 35, 640–644, https://doi.org/10.1111/j.1442-9071.2007.01566.x (2007).
17. Yu, A. K. et al. The comparative histologic effects of subthreshold 532- and 810-nm diode micropulse laser on the retina. Invest Ophthalmol Vis Sci 54, 2216–2224, https://doi.org/10.1167/iovs.12-11382 (2013).
18. Funatsu, H. et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmal 133, 70–77 (2002).
20. Funatsu, H. et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. *Ophthalmology* **112**, 806–816, https://doi.org/10.1016/j.ophtha.2004.11.045 (2005).
21. Funatsu, H., Noma, H., Mimura, T., Eguchi, S. & Hori, S. Association of vitreous inflammatory factors with diabetic macular edema. *Ophthalmology* **116**, 73–79, https://doi.org/10.1016/j.ophtha.2008.09.037 (2009).
22. Vučević, S. et al. Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients. *Acta Ophthalmol* **94**, 56–64, https://doi.org/10.1111/aos.12812 (2016).
23. Hiller, R. J. et al. Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema. *Retina* **37**, 761–769, https://doi.org/10.1097/IAE.00000000000001210 (2017).
24. Sohn, H. J. et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. *Am J Ophthalmol* **152**, 686–694, https://doi.org/10.1016/j.ajo.2011.03.033 (2011).
25. Hiller, R. J. et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. *JAMA Ophthalmol* **136**, 382–388, https://doi.org/10.1001/jamaophthalmol.2018.0179 (2018).
26. Shiraya, T., Kato, S., Araki, F. & Ueta, T. Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema. *Acta Ophthalmol* **95**, e340–e341, https://doi.org/10.1111/aos.13232 (2017).
27. Noma, H. et al. Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema. *Ophthalmologica* **238**, 81–88, https://doi.org/10.1159/000475603 (2017).
28. Shimura, M., Yasuda, K., Motohashi, R., Kotake, O. & Noma, H. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular edema. *Br J Ophthalmol* **101**, 1518–1523, https://doi.org/10.1136/bjophthalmol-2016-309953 (2017).
29. Midena, E. et al. Changes of aqueous humour Müller cells’ biomarkers in human patients affected by diabetic macular edema after sub-threshold micropulse laser treatment. *Retina*, https://doi.org/10.1097/IAE.0000000000002356 (2018).
30. Yao, J. Proteomic analysis of the aqueous humor in patients with wet age-related macular degeneration. *Proteomics Clin Appl* **7**, 8–15, https://doi.org/10.1002/prca.201200102 (2013).
31. Noma, H. et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photoagulation for diabetic macular edema. *Invest Ophthalmol Vis Sci* **52**, 4314–4323, https://doi.org/10.1167/iovs.10-6828 (2011).
32. Maurice, D. Flow of water between aqueous and vitreous compartments in the rabbit eye. *Am J Physiol* **252**, F104–F108 (1987).
33. Del Amo, E. M. Pharmacokinetic aspects of retinal drug delivery. *Prog Retin Eye Res* **57**, 134–185, https://doi.org/10.1016/j.preteyeres.2016.12.001 (2017).
34. Noma, H. et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. *Eye (Lond)* **22**, 42–48, https://doi.org/10.1038/sj.eye.6702498 (2008).
35. Funatsu, H. et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. *Graefes Arch Clin Exp Ophthalmol* **243**, 3–8, https://doi.org/10.1007/s00417-004-0990-7 (2005).
36. Abu-El-Asrar, A. M., Dralands, L., Missotten, L., Al-Jadaa IA, L. & Geboes, K. Expression of apoptosis markers in the retinas of human subjects with diabetes. *FASEB J* **17**, 76–78, https://doi.org/10.1096/fj.02-0157fje (2003).
37. Valverde, A. M. et al. Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy. *Mol Vis* **19**, 47–53 (2013).
38. Joussen, A. M. et al. Suppression of Fas-FasL induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. *Mol Vis* **19**, 47–53, https://doi.org/10.3389/fj.02-0157fje (2013).
39. Grigsby, J. G. et al. Autocrine and paracrine secretion of vascular endothelial growth factor in the pre-hypoxic diabetic retina. *Carr Diabetes Res* **13**, 161–174, https://doi.org/10.1271/157339981266661007165944 (2017).
40. Silva, K. C. et al. Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. *Exp Eye Res* **85**, 123–129 (2007).
41. Takahashi, H. et al. Effects of posterior vitreous detachment on aqueous humor levels of VEGF and inflammatory cytokines. *Br J Ophthalmol* **99**, 1065–1069, https://doi.org/10.1136/bjophthalmol-2014-306051 (2015).
42. Abu El-Asrar, A. M., Imtiaz Nawaz, M., Kangave, D., Siddiquei, M. M. & Geboes, K. Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. *Mediators Inflamm.* **2012**, 493043, https://doi.org/10.1155/2012/493043 (2012).
43. Yu, H., Liu, X. & Zhong, Y. The Effect of Osteopontin on Microglia. *Biomed Res Int* **2017**, 1879437, https://doi.org/10.1155/2017/1879437 (2017).
44. Kowluru, R. A. & Mishra, R. Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy. *Prog Mol Biol Transl Sci* **148**, 67–85, https://doi.org/10.1016/b978-2017.02.004 (2017).
45. Fischer, A. J., Scott, M. A., Zelinka, C. & Sherwood, P. A. Novel of glial cell in the retina is stimulated by insulin-like growth factor 1 and may exacerbate damage to neurons and Muller glia. *Glia* **58**, 633–649, https://doi.org/10.1002/glia.20950 (2010).
46. Bennett, K. L. et al. Proteomic analysis of human qataric aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ®-labelled specimens. *J Proteomics* **74**, 151–166, https://doi.org/10.1016/j.jprot.2010.02.002 (2011).

**Acknowledgements**

The contribution of the IRCCS - Fondazione Bietti has been supported by the Ministry of Health and Fondazione Roma.

**Author Contributions**

E.M. conceived the original idea, designed the study and reviewed the final manuscript. A.M. and G.E. performed the biochemical analysis. L.F. collected and organized the data. E.P. made critical revision of the manuscript. S.B. collected and organized the data and wrote the manuscript. All authors discussed the results and contributed to the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

The work was completed at the University Department of Ophthalmology in Padova, in cooperation with IRCCS - Fondazione Bietti, Rome, Italy

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
